Recent News Coverage
NuvoAir and Security Health Plan of Wisconsin have launched a clinical research study to measure the impact of the company’s virtual care model on reducing exacerbations, ER visits, hospitalizations, readmissions and overall costs for COPD patients.
NuvoAir shared results of its US COPD pilot. Initial data demonstrate the value of NuvoAir's virtual-first clinical service to effectively engage patients, reduce hospitalizations, and improve quality of life.
NuvoAir launches a virtual Asthma Assessment Service designed to increase clinical capacity, reduce time to diagnosis, and provide ongoing remote patient monitoring and management.
NuvoAir Aos, a sensor developed by NuvoAir that can track how inhalers are used by people with COPD or asthma, is now available in Europe. In addition to tracking usage, the Aos sensor also monitors patients’ inhaling technique.
In some way, NuvoAir is comparable to companies like Livongo (which tracks diabetes and has raised $235 million) and Omada Health (which tracks chronic illness and has raised $256.5 million). All these companies are using increasing amounts of data about our health to manage ongoing illnesses.
Cystic fibrosis (CF) patients who monitored their lung function at home using NuvoAir‘s handheld spirometer and smartphone app were able to better engage in telemedicine, a U.K. survey found, with these patients reporting a more than 30% drop in their number of scheduled and urgent in-person consultations.